Long Term Follow Up (LTFU)
Showing 1 - 25 of >10,000
(LTFU) of Patients Treated With Genome-edited Autologous
Not yet recruiting
- Sickle Cell Disease
- OTQ923
- (no location specified)
Nov 24, 2023
Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
Not yet recruiting
- Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
- +2 more
-
Auckland, New Zealand
- +2 more
Jan 24, 2023
(LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
Active, not recruiting
- Hemophilia B
- +2 more
- SB-318
- +2 more
-
Oakland, California
- +4 more
Jan 30, 2023
T-GENVIH-003 LTFU (Long Term Follow Up) Study
Not yet recruiting
- Hernia
- +3 more
- Integra® Gentrix® Surgical Matrix
-
Fort Myers, FloridaSurgical Healing Arts
Sep 12, 2023
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Not yet recruiting
- Non Hodgkin Lymphoma
- Long-term Follow-Up
-
Stanford, California
- +4 more
Oct 30, 2023
End-stage Heart Failure Trial in Beijing (Corheart 6 Left Ventricular Assist System)
Completed
- End-stage Heart Failure
- Corheart 6 Left Ventricular Assist System
-
Beijing, Beijing, ChinaFuwai Hospital, Chinese Academy of Medical Sciences
Jun 28, 2023
LTFU Study of Subjects Who Received GRNOPC1
Active, not recruiting
- Spinal Cord Injuries
- Magnetic Resonance Imaging (MRI)
-
Palo Alto, California
- +2 more
Jun 23, 2023
Long-Term Follow-up Protocol
Recruiting
- Dystrophic Epidermolysis Bullosa
- +2 more
-
Rancho Santa Margarita, California
- +2 more
Jun 7, 2021
LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1
Active, not recruiting
- Spinal Cord Injuries
- Magnetic Resonance Imaging (MRI)
-
Los Angeles, California
- +5 more
Aug 2, 2023
Surgery, Incisional Hernia, Wound Infection Trial in Netherlands (Small bites technique, Conventional large bites closure)
Recruiting
- Surgery
- +5 more
- Small bites technique
- Conventional large bites closure
-
Rotterdam, South-Holland, Netherlands
- +8 more
Sep 27, 2023
Tumors Trial in Worldwide (GSK adoptive cell therapy)
Recruiting
- Neoplasms
- GSK adoptive cell therapy
-
Duarte, California
- +37 more
Feb 1, 2022
Patients Previously Treated With Autologous ex Vivo Gene Therapy
Enrolling by invitation
- Adenosine Deaminase Deficiency
- Severe Combined Immunodeficiency (SCID)
- autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)
-
Los Angeles, California
- +1 more
Mar 31, 2022
Trifecta™ Long Term Follow-Up (LTFU) Study
Completed
- Aortic Valve Insufficiency
- +3 more
- Trifecta™ Valve
-
Los Angeles, California
- +10 more
Jan 12, 2021
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program Trial in Worldwide
Recruiting
- Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
- Previously treated CAR-T patients
-
Phoenix, Arizona
- +71 more
Nov 14, 2022
Study of SCM-AGH in Patients Who Completed SCM-APT2001 Study
Active, not recruiting
- Pancreatitis, Acute
- Not Applicable(Observation Study)
-
Bucheon, Gyenggi-do, Korea, Republic of
- +5 more
Jul 12, 2023
HIV-1-infection Trial in San Francisco, Saint Louis, Camden (EBT-101)
Enrolling by invitation
- HIV-1-infection
- EBT-101
-
San Francisco, California
- +2 more
Oct 17, 2022
Study of Participants Who ReceivedAllogeneic CAR T-Cell Product
Recruiting
- Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical Study
-
Culver City, CaliforniaScience 37, Inc.
Apr 10, 2023
A Long-term Follow-up Study of Patients Who Received VOR33
Recruiting
- Leukemia, Myeloid, Acute
- VOR33
-
La Jolla, California
- +7 more
Aug 9, 2022
Long Term Efficacy and Safety Trial (Imlifidase administered in the 20-HMedIdeS-19 (PAES) study, Best available treatment
Not yet recruiting
- Long Term Efficacy and Safety
- Imlifidase administered in the 20-HMedIdeS-19 (PAES) study
- Best available treatment administered in the 20-HMedIdeS-19 (PAES) study
- (no location specified)
Jun 30, 2023
Following Treatment With Fate Therapeutics' Engineered Cellular
Terminated
- Hematological Malignancy
- Genetically engineered NK cells
-
Phoenix, Arizona
- +4 more
Aug 24, 2022
Study for Patients Treat With WU-CART-007
Enrolling by invitation
- T-cell Acute Lymphoblastic Leukemia
- T-cell Lymphoblastic Lymphoma
- Genetic: WU-CART-007
-
Saint Louis, MissouriWashington University
Aug 18, 2022
Knee Osteoarthritis Who Had Administered FURESTEM-OA Kit Inj. in
Not yet recruiting
- Knee Osteoarthritis
- (no location specified)
Aug 28, 2023
Mobile Application for Follow-up of Cardiac Patients
Recruiting
- Follow-up
- +2 more
- Cardio2U follow-up
-
Edegem, Antwerp, BelgiumUniversity Hospital Antwerp
Jul 10, 2023
Cancer Survivor, Prostate Carcinoma Trial in Duarte (Educational Intervention, Laboratory Biomarker Analysis, Long-term
Active, not recruiting
- Cancer Survivor
- Prostate Carcinoma
- Educational Intervention
- +4 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 31, 2023
Long Term Follow-Up for RGX-111
Enrolling by invitation
- Mucopolysaccharidosis I
- No Intervention
-
Orange, California
- +2 more
Oct 25, 2023